This is a multicenter, open-label Phase II study, aimed at exploring the preliminary efficacy and safety of ZG006 in patients with advanced metastatic NEPC who have previously failed standard treatment.
Male Participants aged 18 to 80 years (inclusive);
Advanced metastatic neuroendocrine prostate cancer;
disease progression after at least one line of platinum-based systemic therapy or intolerance to toxicity;
Measurable disease according to RECIST v1.1 criteria;
Known positive test for human immunodeficiency virus (HIV) or hepatitis；
Patients were deemed unsuitable for participating in the study by the investigator for any reason.
Sequential
ZG006
Biological/VaccineZG006 will be administered as an intravenous (IV) infusion.
Modified Best Overall Response（mBOR）
mBOR will be assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 with Prostate Cancer Working Group 3 (PCWG3) modifications.
Duration of Response (DOR)
Overall Survival (OS)
Disease Control Rate (DCR)
Adverse Events（AE）
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
